ORLANDO, FL, USA (UroToday.com) - Lorie Ellis and colleagues presented their work on the sequence of medications used in patients with metastatic castrate-resistant prostate cancer (mCRPC). They used 3 large datasets, including 2 health care claims registries (Symphony Health Solutions and IMS LifeLink) and one community oncology EMR (Truven Health Marketscan), to identify patients with at least one claim for use of abiraterone, cabazitaxel, docetaxel, enzalutamide, or sipuleucel T. They identified the date of initiation of therapy, proportion of patients receiving 1 vs >1 drug, and the sequence of drugs used.
Review of 5 900 patients showed that the vast majority of mCRPC patients were on one drug (86%, 76%, and 67% in the 3 datasets). Abiraterone was the most commonly used first-line drug (47.6%, 49% and 54.6%), followed by docetaxel (24.5%, 24.7%, 20.6%), enzalutamide (15%, 6.9%, 13.9%), sipuleucel (10.8%, 18.3%, 10.1%), and cabazitaxel (2%, 1%, < 1%). The most common sequences of first- to second-line therapies were abiraterone-enzalutamide (3.2%, 2.9%, 7.8%), abiraterone-docetaxel (1.3%, 4.6%, 4.9%), and docetaxel-abiraterone (1.9%, 3.3%, 5.4%).
The authors concluded that treatment selection was consistent across all 3 datasets in that most patients were on a single agent, and abiraterone and docetaxel were the most commonly used drugs. Similar patterns were identified in selection of second-line therapy.
Presented by Lorie Ellis, Marie-Helene Lafeuille, Laurence Gozalo, Patrick Lefebvre, Elisabetta Malangone-Monaco, Kathleen Wilson, Kathleen A. Foley, and R. Scott McKenzie at the 2015 Genitourinary Cancers Symposium - "Integrating Biology Into Patient-Centric Care" - February 26 - 28, 2015 - Rosen Shingle Creek - Orlando, Florida USA
Janssen Scientific Affairs, LLC, Horsham, PA; Groupe d'Analyse, Ltee, Montreal, QC, Canada; Groupe d'Analyse, Ltee, Montréal, QC, Canada; Truven Health Analytics, Inc., New York, NY; Truven Health Analytics, Inc., Cambridge, MA
Reported by Nikhil Waingankar, MD, medical writer for UroToday.com